Kornimate/medical-research-clean huggingface dataset:
optical coherence tomography measurements in eyes with band atrophy

Conditions: Vision Disorders

Summary: the study is designed to evaluate the ability of optical coherence tomography and vcc scanning laser polarimetry to measure and identify the pattern of band atrophy of the optic nerve in patients with long standing chiasmal lesions. the hypothesis is that these new technologies are able to identify such pattern. the idea is that by using eyes with band atrophy one is able to investigate the ability of the new technologies in measuring the retinal nerve fiber layer particularly in the nasal and temporal portions of the optic nerve.


Eligibility criteria:
inclusion criteria:patients with long standing chiasmal lesions and temporal visual field defect with the following criteria: 1. visual acuity better than 20/30 2. refractive error less 5 spherical diopter and 3 cylinder diopter 3. temporal field defect exclusion criteria: 1. presence of glaucoma and optic nerve anomalies 2. anormal nasal field

Keywords: band atrophy optical coherence tomography scanning laser polarimetry chiasmal lesions
microwave diathermy for treating nonspecific chronic neck pain

Conditions: Neck Pain

Summary: this randomised controlled trial aims to compare the effect of microwave diathermy (continuous and pulsed modes) with sham microwave diathermy in nonspecific chronic neck pain patients. every patient will also be treated by exercise and transcutaneous electrical neurostimulation (tens). the primary endpoint is to establish whether the use of microwaves is justified in terms of pain relief or reduction of disability in this patients.


Eligibility criteria:
inclusion criteria: * to be between 18 and 65 years old * to be diagnosed with chronic nonspecific neck pain (i.e. during more than 3 months in the absence of red flags (unexplained weight loss, fever, neurological signs, history of cancer, history of inflammatory conditions...) exclusion criteria: * pregnancy * sick leave * litigation * claims because the neck pain.

Keywords: diathermy neck pain
effectiveness of cervical facet joint nerve blocks

Conditions: Neck Pain

Summary: 1. to demonstrate whether: i. facet joint nerve blocks have therapeutic value beyond the duration of local anesthetic effect. ii. adjuvant medications (sarapin and depo-medrol) provide additional relief of cervical facet joint pain when used with facet joint nerve blocks. 2. to demonstrate whether or not there are clinically significant improvements in function of patients who receive cervical facet joint nerve block with or without sarapin and depo-medrol (group ii) compared to patients randomized to group i who receive only local anesthetic blocks. 3. to determine the adverse event profile in both groups.


Eligibility criteria:
inclusion criteria: positive for facet joint pain with comparative local anesthetic blocks candidates are over 18 years of age subjects with a history of chronic, function limiting neck pain of at least six months in duration subjects who are able to give voluntary, written informed consent to participate in this investigation subjects who, in the opinion of the investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the center for all the required post-operative follow-ups the subject has not had recent surgical procedures within the last three months. exclusion criteria: negative or false-positive response to controlled comparative local anesthetic blocks narcotic use of greater than hydrocodone 100 mg/day, methadone 80 mg or morphine 100 mg, or dose equivalent uncontrolled major depression or uncontrolled psychiatric disorders uncontrolled or acute medical illnesses including coagulopathy, renal insufficiency, chronic liver dysfunction, progressive neurological deficit, urinary sphincter dysfunction, infection, increased intercranial pressure, pseudotumor cerebri, intercranial tumors, unstable angina, and severe chronic obstructive pulmonary disease. chronic severe conditions that could interfere with the interpretations of the outcome assessments for pain and bodily function women who are pregnant or lactating subjects who have participated in a clinical study with an investigational product within 30 days of enrollment patients with multiple complaints involving concomitant hip osteoarthritis, will not be amenable to study due to the overlap of pain complaints. inability to achieve appropriate positioning and inability to understand informed consent and protocol history of adverse reaction to local anesthetic or anti-inflammatory drugs
trial of different hypothermia temperatures in patients recovered from out-of-hospital cardiac arrest

Conditions: Non-environmental Hypothermia; Cardiac Arrest

Summary: mild therapeutic hypothermia in the temperature range of 32º - 34ºc. improves survival in patients recovered from a ventricular fibrillation cardiac arrest. the same therapy is suggested with less evidence for asystole as first rhythm after cardiac arrest. the purpose of this study is to determine whether different temperature targets (32º vs 34º) may have different efficacy in the treatment of post-cardiac arrest patients. if successful, this pilot study will eventually form the basis for a larger, multicentric randomized clinical trial.

patients admitted consecutively were potentially eligible for the study if they had a witnessed out-off hospital cardiac arrest (ohca) apparently related to heart disease and an interval of \<60 minutes from collapse to return of spontaneous circulation (rosc). additional inclusion criteria were: 1. age \>18 years. 2. initial registered rhythm of a shockable rhythm (ventricular fibrillation or pulseless ventricular tachycardia) or asystole. exclusion criteria were: 1. known pregnancy 2. glasgow coma scale score after rosc \>8. 3. cardiogenic shock (a systolic blood pressure of \ 30 minutes). 4. other nonshockable rhythms (pulseless electric activity). 5. terminal illness present before the ohca. 6. possible causes of coma other than cardiac arrest (drug overdose, head trauma, or cerebrovascular accident).

Eligibility criteria:
inclusion criteria: * age \> 18 * resuscitated patients from a cardiac arrest with first rhythm of ventricular fibrillation or asystole * witnessed cardiac arrest * estimated delay between cardiac arrest and advanced resuscitation \< 20 min. * resuscitation time from first contact to recovery of spontaneous circulation \< 60 min. * hemodynamic stability (mean blood pressure \[bp\] \>60 mmhg), with or without inotropic drugs, before randomization * glasgow coma score \<9 without sedation before randomization exclusion criteria: * pregnant women or suspected pregnancy or fertile women without a negative pregnancy test * suspected non-cardiac arrest caused coma * electrical instability (uncontrollable life-threatening arrhythmias) * hemodynamic instability (mean bp ≤60 mmhg), refractory to volume infusion or inotropic drugs * refractory hypoxemia (saturation \<85% with fio2=100%) * previous known terminal illness * active bleeding or known coagulopathy * opposition from patient's family to enter the study

Keywords: hypothermia, induced cardiac arrest disability evaluation cardiac arrhythmia ventricular function internal cooling out-of-hospital cardiac arrest post-cardiac arrest syndrome
study of predictive factors of chemoresistance in ovarian cancer

Conditions: Ovarian Cancer

Summary: epithelial ovarian cancer (eoc) has a poor prognosis. eoc management requires debulking surgery and chemotherapy based on taxol and carboplatine. initial response is often good, but most often a recurrence occurred in the first 18 months. early recurrence signs chemoresistance and palliative treatment. the study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.


Eligibility criteria:
inclusion criteria: * patient \> 18 years of age * patient with histological proven epithelial ovarian cancer exclusion criteria: * patients who can not give their own consent * patients without ovarian cancer

Keywords: ovarian cancer chemo resistance predictive factors cohort study bio bank
quality of life of hiv-infected participants switched to raltegravir versus other antiretroviral regimens (mk-0518-266)

Conditions: Human Immunodeficiency Virus

Summary: this is a multi-center, longitudinal observational study of adult human immunodeficiency virus (hiv) participants at academic and community-based practices in the united states who are switching from first-line to second-line therapy. the study's primary hypothesis is that hiv participants switching to raltegravir-based regimens will have better medical outcomes study-hiv (mos-hiv) health survey scores than participants switched to non-nucleoside reverse transcriptase inhibitor (nnrti)-based or protease inhibitor (pi)-based regimens.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of hiv * switching antiretroviral regimen(s) for the first time at the start of the study exclusion criteria: * currently pregnant * presence of active tuberculosis, hepatitis b, and/or hepatitis c and receiving treatment for the condition(s) during the study period * presence of active pneumonia or other signs of opportunistic infections at the start of the study * currently participating in a clinical trial

Keywords: hiv infections anti-hiv agents anti-retroviral agents nucleoside reverse transcriptase inhibitors non-nucleoside reverse transcriptase inhibitor protease inhibitors
interest of intensive postoperative rehabilitation following minimally invasive lung resection

Conditions: Lung Cancer

Summary: for patients diagnosed with non-small cell lung cancer (nsclc), lung resection surgery remains the gold standard for curative treatment. this scheduled operation is associated with significant morbidity, particularly in individuals with impaired cardio-respiratory function. therefore, patient optimization is paramount. the process begins prior to surgery with preoperative rehabilitation, commonly referred to as "prehabilitation," serving as the foundation for various enhanced recovery after surgery programs. the training methods employed in these programs bear similarity to rehabilitation programs designed for patients with chronic obstructive pulmonary disease (copd). postoperatively, patients undergoing thoracic surgery partake in daily physiotherapy sessions, aiming to optimize the postoperative period, minimize the respiratory impact of surgery, and reduce the length of hospital stay. however, this treatment is not currently standardized and primarily involves early mobilization, including walking, and respiratory physiotherapy. our focus is on the intensity and methods of this postoperative rehabilitation. there is limited literature on effective early rehabilitation in the immediate postoperative period, and existing studies suggest no adverse events associated with postoperative training. therefore, our objective is to assess whether combining endurance training with standard physiotherapy (walking and respiratory physiotherapy) enhances the functional capacity of individuals undergoing lung surgery.


Eligibility criteria:
inclusion criteria: * patients requiring surgery for diagnosed or undergoing diagnosis of lung cancer. * patients in need of major lung resection through a minimally invasive approach. * patients capable of performing the chair rise test. exclusion criteria: - contraindications to cyclo-ergometry: deep vein thrombosis in a lower limb. patients with one or both lower limbs amputated. rheumatological pathology, trauma, or previous surgery in the lower limb, pelvis, or spine, resulting in limited joint amplitude or strict immobilization. dermatological conditions with severe lesions preventing prolonged sitting on a bicycle. * glasgow score less than 15. * patients who have not undergone pulmonary resection by minimally invasive surgery. * patients hospitalized outside the thoracic surgery department before the first post-operative visit with the physiotherapist on day 0.
upper limb activity in human sci rehabilitation

Conditions: Spinal Cord Injury

Summary: functional recovery following sci in adults is limited. improvements in the quality of life of affected persons are associated with the recovery of functions that allow independent living, for example use of the arms and hands. rehabilitative training has been shown to aid upper limb recovery. however, there are likely vast differences in the amount of time individuals spend actively training (during rehabilitation sessions in the clinic) and what they do in their non-training time (during daily life). the activity, or lack of, during the non-training period could interfere (positively or negatively), with the specific training in the rehabilitation session. however, there is little information available about this. inertial measurement units are increasingly being used in human movement and rehabilitation research. the use of such technology is a promising approach to rapidly and discreetly collect objective movement information. the investigators plan to introduce a novel, long-term, activity sensor into clinical sci rehabilitation. the investigators use this sensor to precisely measure movement of the upper limb over extended periods of time. upper limb activity recordings from these sensors allow us to detail the amount and duration of activity during specific periods of upper limb rehabilitation and recovery. the investigators aim is to measure upper limb activity. the investigators aim to track changes in the activity of the upper limb during recovery and rehabilitation in patients with cervical sci as well as collect reference values of upper limb activity in chronic sufferers. the recordings from this activity sensor will provide a more detailed understanding of how everyday upper limb activity contributes to functional recovery.


Eligibility criteria:
inclusion criteria: * tetraplegic and paraplegic subjects. * males and females aged 18 or older. * acute (defined here as \ 90 days after admission of sci) for the cross-sectional study, all levels of injury, complete and incomplete, traumatic and non-traumatic injuries. * good enough cognitive ability to be able to follow simple verbal instructions. * signed informed consent before study onset. exclusion criteria: * a neurological disease other than sci, which is expected to affect the upper limb function, i.e. plexus paresis. * an orthopaedic or rheumatologic disease, e.g. osteoarthritis, which is expected to affect the upper limb function. * pre-morbid on-going major depression or psychosis.
thrombx retriever for acute ischemic stroke trial

Conditions: Ischemic Stroke

Summary: this trial is designed to assess the safety and effectiveness of the thrombx retriever.

this trial is a clinical evaluation is to assess the safety and effectiveness of the thrombx retriever in the revascularization of the site of primary occlusion in patients presenting with acute ischemic stroke secondary to intracranial, large vessel, occlusive disease.

Eligibility criteria:
inclusion criteria: * acute anterior circulation ischemic stroke * pre-stroke modified rankin score ≤ 1 * nihss ≥ 6 and \< 25 immediately prior to enrollment * aspect score ≥6 with ct scanning or core infarct volume \<50 ml on magnetic mri or ct based perfusion imaging * occlusion of ic or the middle cerebral artery m1 or m2 division * subject can be treated within eight-hours of onset of stroke symptoms exclusion criteria: * pregnant or lactating at time of admission * known serious sensitivity to radiographic contrast agents * known sensitivity to nickel, titanium metals, or their alloys * current participation in another investigation drug or device treatment study * known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency prothrombin time lab results to be available prior to enrollment) * renal failure * baseline blood glucose of \ 400mg/dl (22.20 mmol/l) * baseline platelet count \< 50,000/ul * severe, sustained hypertension * presumed septic embolus, suspicion of bacterial endocarditis * subject has a contraindication to an angiogram * life expectancy \<6 months * comorbid disease or condition that would confound assessments * known history of arterial tortuosity, preexisting stent, and/or other arterial disease * tandem lesions, occlusion requiring angioplasty and/or stent placement or evidence of carotid dissection * site of occlusion is heavily calcified * imaging or clinical evidence of bilateral strokes or concomitant posterior circulation stroke * ct or mri evidence of hemorrhage or evidence of mass effect or intra-cranial tumor * imaging evidence suggests subject is not appropriate for mechanical thrombectomy
cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab pateinets with aggresive nhl

Conditions: Lymphoma; Non Hodgkin's Lymphoma

Summary: we now propose to investigate the combination of chop-rituxan plus peg-filgrastim (peg-filgrastim) and gm-csf. peg-filgrastim would be given in order to allow us to administer the chemotherapy courses every 2 weeks with the practical advantage of requiring only one dose of peg-filgrastim instead of daily doses of g-csf.

1.1 primary objective: 1. to identify the ideal dose of the combination of chop-r with peg-filgrastim (neulasta) using first a fixed dose of neulasta and an escalating dose of gm-csf (leukine) up to 250 mcg. when that dose is reached, if possible, the dose of neulasta will be increased stepwise. chop-r will be delivered every 14 days at a fixed standard dose with dose adjustments of peg-filgrastim and gm-csf upwards and downwards according to nadir or zenith blood counts. 1.2 secondary objective: 2. to generate preliminary pilot data as to the effectiveness of the regimen in inducing very early remissions as measured by the ct-pet scan technique.

Eligibility criteria:
inclusion criteria: * patients with previously untreated aggressive non-hodgkin's lymphoma. aggressive histologies include follicular large cell, diffuse large cell, peripheral t cell, transformed lymphomas, lymphoblastic lymphomas, burkitt and burkitt like lymphomas. * must have measurable or evaluable disease. * stage i-iv patients are eligible * patients must be 18 years or older. * no evidence of grade 3 or more neurosensory or neuromotor dysfunction (see appendix- toxicity criteria) * written consent exclusion criteria: * hiv positive patients and those with hepatitis b or c will be excluded from this protocol. * patients with inadequate bone marrow and organ function as defined below: * neutrophils \<1,000/l * platelets \<100,000/l * billirubin \>2 * creatinine \>2.0 or estimated crcl \<30 cc/min * cns involvement by lymphoma. * uncontrolled intercurrent disease including arrhythmias, angina pectoris, class iii-iv congestive heart failure (chf symptoms on less than ordinary exertion or at rest) or active infection. * active infection or fever \> 38.2 degrees c unless due to lymphoma. * subject is not using adequate contraceptive precautions. * pregnancy or breast feeding

Keywords: aggressive non-hodgkin's lymphoma
to compare the pharmacokinetics profiles of iso 20, ibu 200 and ibu plus iso combinations 200 + 20

Conditions: Duchenne Muscular Dystrophy (DMD)

Summary: this study will evaluate the pharmacokinetics plasma profile of 3 treatments: iso 20, ibu 200 and ibu and iso combinations (200 +20) given in single dose. this study is being conducted to support the submission for new indication in treatment of the combinations of isosorbide dinitrate and ibuprofen as a treatment for duchenne muscular dystrophy.

this trial is designed to define drug interactions following the combined administration of isosorbide dinitrate, a no donor, and ibuprofen, nsaid, a through pharmacokinetics approach. both ibuprofen and isosorbide dinitrate were licensed worldwide. ibuprofen is approved for use in adults and children; isosorbide is approved for use in adults. ibuprofen is currently used in pediatric patients as a first line anti-inflammatory and antipyretic agent. consensus exists that among nsaids ibuprofen is the one endowed with less adverse effects (see note 66 of the italian drug agency aifa and mea). no specific studies concerning safety and tolerability of isdn in pediatric patients have been reported.

Eligibility criteria:
inclusion criteria: * healthy free-living * males between the age of 18 and 27 * normal ecg * body mass index of 19.0-29.0 (kg/m2) * subject healthy in the opinion of the investigator * signed informed consent after verbal and written information exclusion criteria: * clinically significant underlying systemic illness that may preclude the subject's ability to complete the trial * any gastrointestinal conditions which, in the opinion of the investigator, may interfere with the absorption of the drug or render the subjects unable to take oral medication (gastric ulcer, peptic ulcer, stomach acid, frequent diarrhea, gastrointestinal surgery) * history of the following cardiac diseases sbp \<120 mmhg or dbp \< 80 mmhg * platelet count \< 100000/mm3 * history of recurrent headache * history of ongoing or clinically relevant glaucoma * history of alcohol, drug or medication abuse within the past 2 years * treatment with norepinephrine, acetylcholine and histamine * history or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation * participation in another study phase 1 with any investigational product within 6 months of screening

Keywords: dmd duchenne muscular dystrophy
mediators of inflammation, prognostic markers and genetic polymorphisms in patients with sepsis

Conditions: Sepsis

Summary: aims of the study were to find vascular markers of inflammation and endothelial damage during the course of severe sepsis in septic patients and the effects of treatment with anti-inflammatory medication (such as drotregocin alfa (activated)). another aim is to find new markers and gene polymorphisms for prognosis and mortality of patients with severe sepsis. the hypothesis is that higher plasma concentrations of certain markers in septic patients are associated with a higher mortality rate.

during the past years many investigators have focused on the immunological changes in sepsis disease, and great attention has been paid to the development of practicable means of immunomonitoring. human activated protein c (drotrecogin alfa (activated)), an important coagulation inhibitor plays a major role in regulating microvascular coagulation, inflammation and immunology. little is known about prognostic vascular biomarkers during the time course of patients with severe sepsis.

Eligibility criteria:
inclusion criteria: * sirs-criteria * proven infection * one sepsis-induced organ-failure * adults \<18 years old exclusion criteria: * anemia * pregnancy * blood donor in the last 3 month

Keywords: severe sepsis prognostic markers polymorphisms sirs